Pentoxifylline.
Pentoxifylline (oxpentifylline) is a methylxanthine derivative with potent hemorrheologic properties. In the United States it is marketed for the treatment of intermittent claudication. Human and animal studies have shown that pentoxifylline therapy results in a variety of physiological changes at the cellular level, which may be important in treating a diverse group of human afflictions. Immune modulation includes increased leukocyte deformability and chemotaxis, decreased endothelial leukocyte adhesion, decreased neutrophil degranulation and release of superoxides, decreased production of monocyte-derived tumor necrosis factor, decreased leukocyte responsiveness to interleukin 1 and tumor necrosis factor, inhibition of T and B lymphocyte activation, and decreased natural killer cell activity. Hypercoagulable states improve through decreased platelet aggregation and adhesion, increased plasminogen activator, increased plasmin, increased antithrombin III, decreased fibrinogen, decreased alpha 2-antiplasmin, decreased alpha 1-antitrypsin, and decreased alpha 2-macroglobulin. Wound healing and connective tissue disorders may respond to an increase in fibroblast collagenases and decreased collagen, fibronectin, and glycosaminoglycan production. Fibroblast responsiveness to tumor necrosis factor is also diminished. Potential medical uses of pentoxifylline are reviewed.
Samlaska
C P
CP
Dermatology Service, Tripler Army Medical Center, Honolulu, Hawaii.
Winfield
E A
EA
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D003238:Connective Tissue / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D010431:Pentoxifylline / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D014783:Viscosity; D014945:Wound Healing / Q000187:drug effects
D010431:Pentoxifylline